Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Bad Ad Program's Light Penetrate Murky CME, Clinical Trial Practices?

Executive Summary

The "Bad Ad" program already has proven to be a great success in motivating health care providers to report well-known forms of false or misleading drug promotion, such as ads that overstate efficacy and minimize risks, but can it help address more subtle and difficult-to-detect forms of questionable drug promotion, such as those that are hidden in drugmakers' support of professional education and clinical trials?

You may also be interested in...



Pfizer's "Online Resources" Are Over The Line For FDA

Reintegrating the principles in its seminal citations of search engine ads, DDMAC tells Pfizer to stop including "riskless" links for named drugs as part of its Lipitor website.

"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One

In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.

"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One

In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.

Related Content

Topics

UsernamePublicRestriction

Register

PS053504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel